RxDoctor Payments Data

Heath Penland

Psychiatry · Huntsville, ALNPI 1649293630

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.5% of the total across 565 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,743in general payments, 2019–2025

Across 565 payments — averaging $19.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Otsuka America Pharmaceutical, Inc.$1K
  • Bausch Health US, LLC$882
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$775
  • Takeda Pharmaceuticals U.S.A., Inc.$655
  • Axsome Therapeutics, Inc.$625
  • plus $5K from 22 others

What the payments were for

  • Food & beverage$10,694100%
  • Education$490%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,743 in reported general payments places this provider in the 90th percentile of 400 psychiatry providers in Alabama.

See all psychiatry providers in Alabama

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl14$31,000
Rivastigmine14$2,652
Lisdexamfetamine Dimesylate12$1,975
Clozapine12$1,534
Duloxetine Hcl55$1,438
Bupropion XlBupropion Hcl43$1,396
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine46$1,120
Methylphenidate Hcl34$1,060
Bupropion Hcl SrBupropion Hcl15$858
Aripiprazole27$722
Trazodone Hcl26$663
Lamotrigine68$653
Desvenlafaxine Succinate ErDesvenlafaxine Succinate19$589
Quetiapine Fumarate67$572
Venlafaxine Hcl ErVenlafaxine Hcl20$534

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,567$31,00014 claims
Almatica Pharma LLCSertraline Hcl$553$17723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 400 psychiatry providers in Alabama.

Other psychiatry in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →